
StudyFinder
HM2024-18 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Recruiting
This study is testing an compound called TP-3654, which is an investigational product being developed for Myelofibrosis.
Male or Female
18 years and over
Inclusion Criteria:
• diagnosis of primary or secondary myelofibrosis
• may be restricted from strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work
• see link to clinicaltrials.gov for complete inclusion criteria which are specified by diagnosis
Exclusion Criteria:
• eligible for allogeneic bone marrow or stem cell transplantation
• history of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within the past 6 months
• history of chronic liver disease
• women who are pregnant or breastfeeding -see link to clinicaltrials.gov for complete exclusion criteria which are specified by diagnosis
Drug: Momelotinib, Drug: Nusivertib, Drug: Ruxolitinib
Cancer, Rare Diseases
Clinics and Surgery Center (CSC), Myelofibrosis
Naveen Premnath - premn007@umn.edu
Naveen Premnath
PHASE1
STUDY00023042
See this study on ClinicalTrials.gov